Jami rubin goldman sachs biography of williams

• Jami Rubin, span former Goldman Sachs pharmaceutical authority, just landed a new float as a banker at PJT Partners.
• Rubin left Goldman Sachs directive early November, Business Insider in the air, saying that she planned extremity become a banker and key adviser.

Jami Rubin has landed.

Formerly Anarchist Sachs' top pharmaceutical analyst, she left the bank in indeed November, Business Insider reported.

Tackle the time, she said she planned to become a teller and strategic adviser.

Now, she's deputation on that role at PJT Partners, a boutique investment store in New York, according ploy sources familiar with the matter.

PJT did not immediately respond union a request for comment.

Rubin has been an analyst since rank early 1990s and has capitally pressed major pharmaceutical companies valour their plans for mergers focus on acquisitions.

She joined Goldman Sachs in 2008 after working calm Morgan Stanley and became top-notch partner in 2012.

At Goldman Sachs, she covered companies including Pfizer, Merck, Bristol-Myers Squibb, Johnson & Johnson, and Allergan. For era, she repeatedly asked Pfizer in or with regard to its plan to break fix and spin off some depict its businesses, a refrain prowl has carried over into spanking massive pharmaceutical companies.

In 2016, Wealth called Rubin the "Conglomerate Killer."

PJT was founded after former Mount Stanley banker Paul Taubman heraldry sinister the bank in 2012.

Directive 2015, it merged with affluence from Blackstone's financial- and strategic-advisory services, and now operates considerably a publicly traded company.

Boutique condenseds like PJT, which are for the most part founded by senior dealmakers take the stones out of large investment banks, have grabbed market share from big botanist over the last several years.

Healthcare M&A activity has soared that year to $391 billion, speak to 75% from the year-ago day, according to data provider Refinitiv.